# High-dose methylprednisolone mediates YAP/TAZ-TEAD in vocal fold fibroblasts with macrophages

**Authors:** Ryosuke Nakamura, Renjie Bing, Gary J. Gartling, Michael J. Garabedian, Ryan C. Branski

PMC · DOI: 10.21203/rs.3.rs-4626638/v1 · 2024-07-19

## TL;DR

This study explores how high-dose methylprednisolone affects fibroblast and macrophage interactions in vocal folds, revealing a dual effect on inflammation and fibrosis.

## Contribution

The study identifies YAP/TAZ-TEAD signaling as a novel mediator of methylprednisolone's effects in vocal fold fibroblasts.

## Key findings

- Methylprednisolone reduced inflammatory gene expression in fibroblasts co-cultured with M(IFN/LPS) macrophages.
- High-dose methylprednisolone increased fibrotic gene expression and YAP/TAZ nuclear localization.
- Verteporfin partially reversed the fibrotic effects of methylprednisolone.

## Abstract

The pro-fibrotic effects of glucocorticoids may lead to a suboptimal therapeutic response for vocal fold (VF) pathology. Targeting macrophage-fibroblast interactions is an interesting therapeutic strategy; macrophages alter their phenotype to mediate both inflammation and fibrosis. In the current study, we investigated concentration-dependent effects of methylprednisolone on the fibrotic response, with an emphasis on YAP/TAZ-TEAD signaling, and inflammatory gene expression in VF fibroblasts in physical contact with macrophages. We sought to provide foundational data to optimize therapeutic strategies for millions of patients with voice/laryngeal disease-related disability. Following induction of inflammatory (M(IFN/LPS)) and fibrotic (M(TGF)) phenotypes, THP-1-derived macrophages were seeded onto HVOX vocal fold fibroblasts. Cells were co-cultured +/−0.3–3000nM methylprednisolone +/− 3μM verteporfin, a YAP/TAZ inhibitor. Inflammatory (CXCL10, TNF, PTGS2) and fibrotic genes (ACTA2, CCN2, COL1A1) in fibroblasts were analyzed by real-time polymerase chain reaction after cell sorting. Ser211-phosphorylated glucocorticoid receptor (S211-pGR) was assessed by Western blotting. Nuclear localization of S211-pGR and YAP/TAZ was analyzed by immunocytochemistry. Methylprednisolone decreased TNF and PTGS2 in fibroblasts co-cultured with M(IFN/LPS) macrophages and increased ACTA2 and CCN2 in fibroblasts co-cultured with M(IFN/LPS) and M(TGF). Lower concentrations were required to decrease TNF and PTGS2 expression and to increase S211-pGR than to increase ACTA2 and CCN2 expression and nuclear localization of S211-pGR. Methylprednisolone also increased YAP/TAZ nuclear localization. Verteporfin attenuated upregulation of CCN2, but not PTGS2 downregulation. High concentration methylprednisolone induced nuclear localization of S211-pGR and upregulated fibrotic genes mediated by YAP/TAZ activation.

## Linked entities

- **Genes:** CXCL10 (C-X-C motif chemokine ligand 10) [NCBI Gene 3627], TNF (tumor necrosis factor) [NCBI Gene 7124], PTGS2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 5743], ACTA2 (actin alpha 2, smooth muscle) [NCBI Gene 59], CCN2 (cellular communication network factor 2) [NCBI Gene 1490], COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277], YAP1 (Yes1 associated transcriptional regulator) [NCBI Gene 10413], TAFAZZIN (tafazzin, phospholipid-lysophospholipid transacylase) [NCBI Gene 6901], sd (scalloped) [NCBI Gene 32536]
- **Proteins:** yki (yorkie)
- **Chemicals:** methylprednisolone (PubChem CID 6741)

## Full-text entities

- **Genes:** IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}, CXCL10 (C-X-C motif chemokine ligand 10) [NCBI Gene 3627] {aka C7, IFI10, INP10, IP-10, SCYB10, crg-2}, PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}, ACTA2 (actin alpha 2, smooth muscle) [NCBI Gene 59] {aka ACTSA, SMDYS}, YAP1 (Yes1 associated transcriptional regulator) [NCBI Gene 10413] {aka COB1, YAP, YAP-1, YAP2, YAP65, YKI}, NR3C1 (nuclear receptor subfamily 3 group C member 1) [NCBI Gene 2908] {aka GCCR, GCR, GCRST, GR, GRL}, TAFAZZIN (tafazzin, phospholipid-lysophospholipid transacylase) [NCBI Gene 6901] {aka BTHS, CMD3A, EFE, EFE2, G4.5, LVNCX}, PTGS2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 5743] {aka COX-2, COX2, GRIPGHS, PGG/HS, PGHS-2, PHS-2}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CCN2 (cellular communication network factor 2) [NCBI Gene 1490] {aka CTGF, HCS24, IBP-8, IGFBP8, KMD, NOV2}, COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277] {aka CAFYD, EDSARTH1, EDSC, OI1, OI2, OI3}
- **Diseases:** vocal fold (VF) (MESH:D014826), fibrosis (MESH:D005355), Inflammatory (MESH:D007249), voice/laryngeal disease-related disability (MESH:D014832)
- **Chemicals:** LPS (MESH:D008070), Verteporfin (MESH:D000077362), Methylprednisolone (MESH:D008775)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** THP-1 — Homo sapiens (Human), Childhood acute monocytic leukemia, Cancer cell line (CVCL_0006), S211 — Homo sapiens (Human), Transformed cell line (CVCL_U658)

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11276011/full.md

---
Source: https://tomesphere.com/paper/PMC11276011